INKT
MiNK Therapeutics, Inc.
$11.34
-4.47%
$58.9M
No data for this timeframe.
Vol
Market Cap$58.9M
Cap SizeMicro Cap
Analyst ConsensusStrong Buy (88%)
Inst. Holders5 funds
Inst. Value$878.0K
Inst. Activity1 buys / 1 sells
Insider Activity0B / 5S
Insider Net $-$18.4K
SEC Reports4
Press Releases9
Exchange Nasdaq·Sector Biological Products, (No Diagnostic Substances)·Inc. DE·CIK 0001840229·Prev Close $11.87
Recent Activity
Jun 4, 2026
Insider
Ryan Barbara sold 500 shares
Director @ $12.68 ($6.3K)
Jun 3, 2026
other
MiNK Therapeutics Announces its Virtual 2026 Annual Shareholders Meeting
<p>NEW YORK, June 03, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data
Jun 1, 2026
Insider
Ryan Barbara sold 1,434 shares
Director @ $12.38 ($17.8K)
Jun 1, 2026
Insider
WIINBERG ULF sold 1,131 shares
Director @ $12.38 ($14.0K)
May 28, 2026
Press
MiNK Therapeutics announced first patient dosing in a randomized Phase 2 trial (C-1300-02) evaluating agenT-797 for seve
Impact 4/10
May 20, 2026
Press
MiNK Therapeutics presented a single-case report at ATS 2026 showing that sequential immunotherapy with Anktiva (N-803)
Impact 4/10
May 15, 2026
SEC
MiNK Therapeutics reported Q1 2026 results with a net loss of $2.7M ($0.57 per share), beating consensus estimates of -$
8-K — Impact 5/10
May 15, 2026
SEC
MiNK Therapeutics reported Q1 2026 EPS of -$0.57, beating consensus of -$0.77 by 26%, with net loss narrowing to $2.7M f
PRESS-RELEASE — Impact 6/10
Price Targets
$39.00
+229.9% upside
Strong Buy
Current $11.82
Low $35.00
Median $39.00
High $43.00
2 analysts
$35.00
$43.00
Analyst Ratings
2Strong Buy
5Buy
1Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| May 18, 2026 | HC Wainwright & Co. | REITERATE | Buy → Buy |
| Apr 1, 2026 | HC Wainwright & Co. | REITERATE | Buy → Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.60 ▲ +31.0% | $-0.60 — $-0.60 | 43% YoY | 1 |
| Next Q | $-0.63 ▲ +30.8% | $-0.63 — $-0.63 | 3% YoY | 1 |
| Current FY | $-2.46 ▲ +24.7% | $-2.46 — $-2.46 | 16% YoY | 1 |
| Next FY | $-2.85 ▲ +17.2% | $-3.32 — $-2.39 | -16% YoY | 2 |
Latest Reports
NEUTRAL
Press
4/10
MiNK Therapeutics announced first patient dosing in a randomized Phase 2 trial (C-1300-02) evaluating agenT-797 for seve
May 28, 2026
NEUTRAL
8-K
5/10
MiNK Therapeutics reported Q1 2026 results with a net loss of $2.7M ($0.57 per share), beating consensus estimates of -$
May 15, 2026
BULLISH
PRESS-RELEASE
6/10
MiNK Therapeutics reported Q1 2026 EPS of -$0.57, beating consensus of -$0.77 by 26%, with net loss narrowing to $2.7M f
May 15, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| VANGUARD GROUP INC | $754.3K | DOUBLED |
| RENAISSANCE TECHNOLOGIES LLC | $116.0K | TRIM |
| BANK OF AMERICA CORP | $6.3K | — |
| MORGAN STANLEY | $1.2K | DOUBLED |
| WELLS FARGO & COMPANY/MN | $223.00 | — |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Jun 4, 2026 | Ryan Barbara | SELL | $6.3K |
| Jun 1, 2026 | Ryan Barbara | A | $17.8K |
| Jun 1, 2026 | WIINBERG ULF | A | $14.0K |
| Jun 1, 2026 | Holcomb John | A | $13.5K |
| Jun 1, 2026 | Corvese Brian | A | $17.9K |
5 institutional holders with $878.0K total value (78,743 shares) as of 2025-Q4. Top holders: VANGUARD, RENAISSANCE, BANK.
Top Institutional Holders — 2025-Q4
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | VANGUARD GROUP INC | 67,651 | $754.3K | 85.9% | DOUBLED +102.8% |
| 2 | RENAISSANCE TECHNOLOGIES LLC | 10,400 | $116.0K | 13.2% | TRIM -28.8% |
| 3 | BANK OF AMERICA CORP /DE/ | 568 | $6.3K | 0.7% | — |
| 4 | MORGAN STANLEY | 104 | $1.2K | 0.1% | DOUBLED +422.7% |
| 5 | WELLS FARGO & COMPANY/MN | 20 | $223.00 | 0.0% | — |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| VANGUARD GROUP INC | DOUBLED | 33,351 | 67,651 | +102.8% | $754.3K | 2025-Q4 |
| RENAISSANCE TECHNOLOGIES LLC | TRIM | 14,600 | 10,400 | -28.8% | $116.0K | 2025-Q4 |
| VANGUARD GROUP INC | ADD | 23,744 | 33,351 | +40.5% | $466.9K | 2025-Q3 |
| RENAISSANCE TECHNOLOGIES LLC | NEW | — | 14,600 | — | $204.4K | 2025-Q3 |
| UBS Group AG | DOUBLED | 284 | 5,648 | +1888.7% | $79.1K | 2025-Q3 |
| MORGAN STANLEY | DOUBLED | 22 | 115 | +422.7% | $1.6K | 2025-Q3 |
| VANGUARD GROUP INC | NEW | — | 23,744 | — | $205.1K | 2025-Q1 |
| VANGUARD GROUP INC | EXIT | 234,182 | 0 | -100.0% | $0.00 | 2025-Q1 |
| RENAISSANCE TECHNOLOGIES LLC | EXIT | 101,707 | 0 | -100.0% | $0.00 | 2025-Q1 |
| UBS Group AG | TRIM | 6,212 | 2,847 | -54.2% | $2.0K | 2024-Q4 |
5 unique insiders with 5 transactions. Net insider value: -$18.4K ($0.00 bought, $18.4K sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jun 4, 2026 | Ryan Barbara | Director | SELL | 500 | $12.68 | $6.3K |
| Jun 1, 2026 | Ryan Barbara | Director | A | 1,434 | $12.38 | $17.8K |
| Jun 1, 2026 | WIINBERG ULF | Director | A | 1,131 | $12.38 | $14.0K |
| Jun 1, 2026 | Holcomb John Bradley | Director | A | 1,091 | $12.38 | $13.5K |
| Jun 1, 2026 | Corvese Brian | Director | A | 1,444 | $12.38 | $17.9K |
| Jun 1, 2026 | Behner Peter | Director | A | 1,313 | $12.38 | $16.3K |
| Mar 10, 2026 | Ryan Barbara | Director | SELL | 300 | $15.28 | $4.6K |
| Mar 9, 2026 | Ryan Barbara | Director | SELL | 200 | $10.17 | $2.0K |
| Mar 2, 2026 | Ryan Barbara | Director | A | 1,629 | $10.90 | $17.8K |
| Mar 2, 2026 | Holcomb John Bradley | Director | A | 1,239 | $10.90 | $13.5K |
| Mar 2, 2026 | Behner Peter | Director | A | 1,491 | $10.90 | $16.3K |
| Mar 2, 2026 | Corvese Brian | Director | A | 1,640 | $10.90 | $17.9K |
| Mar 2, 2026 | WIINBERG ULF | Director | A | 1,285 | $10.90 | $14.0K |
| Mar 2, 2026 | Ryan Barbara | Director | SELL | 100 | $10.83 | $1.1K |
| Feb 27, 2026 | Ryan Barbara | Director | SELL | 400 | $10.86 | $4.3K |
| Sep 23, 2025 | Holcomb John Bradley | Director | A | 4,174 | $0.00 | $0.00 |
4 SEC filing reports analyzed. Sentiment: 2 bullish, 0 bearish, 0 mixed, 2 neutral. Avg impact: 5.0/10.
NEUTRAL
8-K
5/10
MiNK Therapeutics reported Q1 2026 results with a net loss of $2.7M ($0.57 per share), beating conse
May 15, 2026
BULLISH
PRESS-RELEASE
6/10
MiNK Therapeutics reported Q1 2026 EPS of -$0.57, beating consensus of -$0.77 by 26%, with net loss
May 15, 2026
NEUTRAL
PRESS-RELEASE
2/10
MiNK Therapeutics issued a press release announcing it will report Q1 2026 financial results before
May 8, 2026
BULLISH
8-K
7/10
MiNK Therapeutics reported Q4 2025 financial results showing a narrower-than-expected net loss of $0
Apr 21, 2026
NEUTRAL
4/10
MiNK Therapeutics announced first patient dosing in a randomized Phase 2 trial (C-1300-02) evaluatin
May 28, 2026
NEUTRAL
4/10
MiNK Therapeutics presented a single-case report at ATS 2026 showing that sequential immunotherapy w
May 20, 2026
BULLISH
7/10
MiNK Therapeutics announced the initiation of a randomized Phase 2 trial (C-1300-02) evaluating its
May 14, 2026
BULLISH
7/10
MiNK Therapeutics presented data at ASGCT 2026 showing its off-the-shelf iNKT cell therapy, agenT-79
May 12, 2026
BULLISH
8/10
MiNK Therapeutics announced positive Phase II trial data for its agenT-797 cell therapy in combinati
Apr 17, 2026
NEUTRAL
3/10
MiNK Therapeutics announced that an abstract featuring its investigational iNKT cell therapy, agenT-
Apr 1, 2026
MIXED
5/10
MiNK Therapeutics reported financial results for Q4 and full year 2025, highlighting a net loss incr
Mar 31, 2026
NEUTRAL
4/10
MiNK Therapeutics announced it will report Q4 and full-year 2025 financial results on March 31, 2026
Mar 17, 2026
BULLISH
7/10
MiNK Therapeutics (INKT) announced a strategic collaboration with C-Further to develop a PRAME-targe
Mar 10, 2026
Current analyst consensus: Strong Buy (88% buy). Based on 8 analysts: 2 strong buy, 5 buy, 1 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$39.00 mean target
+229.9% upside
Strong Buy (3.00)
$35.00 Low
$43.00 High
| Metric | Value |
|---|---|
| Current Price | $11.82 |
| Target Low | $35.00 |
| Target Mean | $39.00 |
| Target Median | $39.00 |
| Target High | $43.00 |
| # Analysts | 2 |
| Recommendation | Strong Buy (3.00) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.60 | $-0.60 | $-0.60 | 43.4% | +31.0% | 1↑ 0↓ | $0.0B | 0.0% | 1 |
| Next Q 2026-09-30 |
$-0.63 | $-0.63 | $-0.63 | 3.1% | +30.8% | 1↑ 0↓ | $0.0B | 0.0% | 1 |
| Current FY 2026-12-31 |
$-2.46 | $-2.46 | $-2.46 | 16.0% | +24.7% | 1↑ 0↓ | $0.0B | 0.0% | 1 |
| Next FY 2027-12-31 |
$-2.85 | $-3.32 | $-2.39 | -16.1% | +17.2% | 1↑ 0↓ | $0.0B | 0.0% | 2 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.600 | |
| 7d ago | $-0.870 | +0.270 |
| 30d ago | $-0.870 | +0.270 |
| 60d ago | $-0.920 | +0.320 |
| 90d ago | $-0.920 | +0.320 |
1 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 0 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| May 18, 2026 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Apr 1, 2026 | HC Wainwright & Co. | REITERATE | Buy | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 2 | 5 | 1 | 0 | 0 | 88% | |
| May 1, 2026 | 2 | 5 | 1 | 0 | 0 | 88% | |
| Apr 1, 2026 | 2 | 5 | 1 | 0 | 0 | 88% | |
| Mar 1, 2026 | 2 | 5 | 1 | 0 | 0 | 88% | |
| Feb 1, 2026 | 2 | 5 | 1 | 0 | 0 | 88% | |
| Jan 1, 2026 | 2 | 5 | 1 | 0 | 0 | 88% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
Jun 3, 2026
other
MiNK Therapeutics Announces its Virtual 2026 Annual Shareholders Meeting
<p>NEW YORK, June 03, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=hdZNduh_qV7vyaMGKbgxqy-DJczLprtXGi52ByICzNEiEWIqd
May 28, 2026
fda
MiNK Therapeutics Announces First Patient Dosed in Randomized Phase 2 Trial of agenT-797 in Acute Lung Injury and Critical Illness
<p>NEW YORK and LVIV, Ukraine, May 28, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=BpxtMJBkReNegAiN6gJGuFzX7JpY6Rkb
May 20, 2026
fda
MiNK Therapeutics Reports New Data on agenT-797, an allo-iNKT Cell Therapy at ATS 2026; Simultaneously Published in Clinical Immunology Communications
<p>NEW YORK, May 20, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=mgxQ-oNLdIDSaQAWRY4IHSV6qMJyAA5FPZTh7Y9gjS8i7Fyhvm
May 15, 2026
earnings
MiNK Therapeutics Reports First Quarter 2026 Financial Results and Advances iNKT Cell Therapy Platform Into Randomized Clinical Validation
<p>NEW YORK, May 15, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=y1VCh6YEj8WTPzfRvr3rFmhpwPGhE5r-YVwDj657wGSTdnmDAP
May 15, 2026
earnings_calendar
INKT Q1 2026 Earnings Before Market Open — 2026-05-15
May 14, 2026
fda
MiNK Therapeutics and First Lviv Territorial Medical Union Initiate Randomized Phase 2 Trial of agenT-797 in Acute Lung Injury and Critical Illness
<p>NEW YORK and LVIV, Ukraine, May 14, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=IrcIjZZP1MGswLI9sKG9VihfogMR_4Lv
May 13, 2026
earnings_calendar
INKT Q1 2026 Earnings Before Market Open — 2026-05-13
May 12, 2026
fda
MiNK Therapeutics Presents Clinical Evidence That a Single, Off-the-Shelf, iNKT Cell Product Drives Context-Dependent Immune Responses at ASGCT 2026
<p>NEW YORK, May 12, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=_VtxxHkCllH9GkueDd0Pf_it15Dwq5GrvCU_Fhwv09nT6Tblin
May 8, 2026
earnings
MiNK Therapeutics to Report First Quarter 2026 Financial Results and Highlight Platform Progress Across iNKT Cell Therapy Programs
<p align="left">NEW YORK, May 08, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=r4MTvq1JFoIqFh-unB9_vlttyI0G24dtNlDKf
Apr 17, 2026
fda
MiNK Therapeutics Reports Phase II Data on Immune Reprogramming and Durable Survival in PD-1 Refractory Gastroesophageal Cancer
<p align="left">NEW YORK, April 17, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=zva0iLIpiK6WoalyfX2sH8vRNTbH_Q3iPA7
Apr 3, 2026
routine
MiNK Therapeutics and Memorial Sloan Kettering to Present Phase II Study of agenT-797 Combination in PD-1 Refractory Gastroesophageal Cancer at AACR 2026
<p>NEW YORK, April 03, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=gpllq0UJ62rMjfieDAjS2LxbMHTue0cROhVYPTmZYZJ6wKrc
Apr 2, 2026
routine
MiNK Therapeutics to Present New Data at ASGCT 2026 Highlighting Context-Dependent Activity of iNKT Cell Therapy
<p>NEW YORK, April 02, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=cRfuQETFsCBzDgSnK2pkMhG9gdJRP6eoEZJXRVEQhfmmN-Pe
Apr 1, 2026
fda
MiNK Therapeutics Announces Abstract Acceptance for Presentation at the American Thoracic Society (ATS) 2026 International Conference
<p>NEW YORK, April 01, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=nsvxX5QQVBRDCScrwrqpR3MkdpAMI6qOzK7mMUFRKrWBzDkN
Mar 31, 2026
earnings
MiNK Therapeutics Reports Q4 and Full Year 2025 Results; Phase 2 Programs Advance with Impactful Non-Dilutive Momentum
<p>NEW YORK, March 31, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=TLvv153iuDBkpodteEB8nGIp92qwbD8EPBvR9TQsl0urpi1r
Mar 17, 2026
earnings
MiNK Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Highlight Platform Expansion Across iNKT Cell Therapy Programs
Recent milestones include strategic collaboration with C-Further to advance PRAME-targeted iNKT cell therapy for pediatric cancers, with meaningful do